EU Grants Conditional Approval for Roche’s One-Minute Subcutaneous Lunsumio in Follicular Lymphoma
Roche announced that the European Commission has granted conditional marketing authorisation for a new subcutaneous (SC) formulation of Lunsumio (mosunetuzumab) for adults with relapsed…
Read More...
Read More...
